Bionano Genomics (BNGO) Total Non-Current Liabilities (2017 - 2026)

Bionano Genomics has reported Total Non-Current Liabilities for 10 years, with the latest figure at $27.3 million in Q1 2026.

• Quarterly Total Non-Current Liabilities changed N/A year-over-year to $27.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.3 million (changed N/A YoY) and the FY2025 annual result came in at $29.2 million, down 29.39% from the prior year.
• Total Non-Current Liabilities slipped to $27.3 million in Q1 2026 per BNGO's latest filing, from $29.2 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $107.4 million in Q4 2023 and troughed at $27.3 million in Q1 2026.
• A 5-year average of $47.1 million and a median of $42.1 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities jumped 137.86% in 2023, then slumped 61.53% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $45.1 million in 2022, then jumped by 137.86% to $107.4 million in 2023, then plunged by 61.53% to $41.3 million in 2024, then slipped by 29.39% to $29.2 million in 2025, then retreated by 6.24% to $27.3 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $27.3 million, $29.2 million, and $41.3 million for Q1 2026, Q4 2025, and Q4 2024 respectively.